GlobeNewswire

Aptean Extends Its Leadership in the Manufacturing ERP Market With Acquisition of OPTIWARE

Del

ATLANTA, May 02, 2019 (GLOBE NEWSWIRE) -- Aptean, a global provider of mission-critical enterprise software solutions, has acquired OPTIWARE, a leading provider of Overall Equipment effectiveness (OEE) and Enterprise Asset Management (EAM) solutions. The acquisition of OPTIWARE extends Aptean’s capabilities in European marketplaces, a key growth area for the company.

OPTIWARE’s products deliver productivity improvements and optimal utilization of production resources and support the transition of global enterprises towards Industry 4.0 and Smart Manufacturing. Supplying the connection of production equipment and powerful tools for efficiency monitoring, together with one of the most flexible EAM solutions available in the market today.

“The European market is a key strategic growth area for Aptean,” said TVN Reddy, Aptean CEO. “OPTIWARE’s capabilities will forward our growth strategy both in our manufacturing solution suite and in European markets where we’ve targeted for expansion. With their strong focus on efficiency, reliability and productivity we believe that OPTIWARE is an ideal fit with our solution offerings. Aptean now offers a more complete suite of solutions for manufacturers in specific verticals such as food and beverage, chemical, automotive, pharmaceutical, and other manufacturing segments. We are delighted to welcome OPTIWARE to the Aptean family”.

“At OPTIWARE we believe that state-of-the-art functionality, visibility and mobility are prerequisites for catering to our customer’s needs – and that our understanding, experience and forward-thinking is what makes the real difference.” said Michael Ries, CEO of OPTIWARE. “By joining Aptean and becoming part of a larger organization, we’ll access their considerable capabilities and will benefit from Aptean’s expertise in the market. We are excited to join the Aptean team”.

“OPTIWARE has realized a strong growth in both revenue and earnings during our ownership and the company is well positioned to benefit from the increasing digitalization and the Industry 4.0 transformation. After approximately six years ownership, we therefore believe it is time to divest OPTIWARE to a new owner. Based on the experiences and talks during the M&A process, we believe that Aptean is the right partner for OPTIWARE to continue the growth journey.” said Erik Balleby Jensen, CEO and Partner in Capidea and Chairman of OPTIWARE.

Headquartered in Denmark, OPTIWARE has approximately 100 team members across offices in Europe, Asia and the United States who will become part of the Aptean organization. Financial terms of the sale will not be disclosed.

About OPTIWARE
OPTIWARE is the result of the merger between API Maintenance Systems and AXXOS Industry Systems. We help customers streamline their production and maintain high-value capital assets such as plants, facilities and equipment. OPTIWARE is a global company helping customers to gain an edge by optimizing asset reliability, predictability and effectiveness. We do this by offering a unique combination of both Enterprise Asset Management (EAM) and Overall Equipment Effectiveness (OEE) systems. OPTIWARE has supplied the production monitoring solutions AXXOS OEE and the EAM solution API PRO for more than 25 years. OPTIWARE is headquartered in Denmark and has over 500 customers globally.

About Aptean
Aptean is a global provider of mission-critical, industry-specific software solutions. Aptean’s purpose-built ERP and supply chain management solutions help address the unique challenges facing process and discrete manufacturers, distributors, and other focused organizations. Aptean’s compliance solutions are built for companies serving specific markets such as finance, healthcare, biotech and pharmaceuticals. Over 2,500 organizations in more than 20 industries across 54 countries trust Aptean’s solutions at their core to assist with running their operations. To learn more about Aptean and the markets we serve, visit www.aptean.com.

Aptean is a trademark of Aptean, Inc. All other company and product names may be trademarks of the respective companies with which they are associated.

About Capidea
Capidea is a Danish private equity fund making long term investments in competitive small and medium-sized companies. Capidea was established in November 2006 and has a total capital commitment of approximately DKK 2.3 billion / EUR 310 million in three funds. Capidea’s third fond was established in December 2017 with a capital commitment of DKK 860 million / EUR 115 million. In addition to institutional investors, the investor base comprises a number of bluechip companies. Capidea has invested in 19 companies with a total turnover of approx. DKK 5 billion/EUR 670 million, visit www.capidea.dk.


FOR MORE INFORMATION

APTEAN
Media Relations
Mark Pileski
mark.pileski@aptean.com
+1 647.499.6583

OPTIWARE
Michael Ries, CEO
michael.ries@optiware.com
+45 40 27 99 41

CAPIDEA
Erik Balleby Jensen, CEO & Partner
ebj@capidea.dk
+45 21 23 33 36

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CESTPressemelding

New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus

Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CESTPressemelding

ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r

Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CESTPressemelding

American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and

XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CESTPressemelding

AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi

LGC CAPITAL Announces Results of Annual Meeting, Appointment of New Chairman and Approval of Name Change to Elixxer Ltd.23.5.2019 14:00:00 CESTPressemelding

MONTRÉAL, May 23, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) ("LGC" or the “Corporation”) is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held yesterday in Montreal, Quebec. At the Meeting, all five of the nominees listed in the Corporation’s management information circular dated April 17, 2019 were elected as directors, all with a vote of more than 92% of the shares voted in their favour. Accordingly, the directors of LGC for the ensuing year are Mohammed Ghafari, Mazen Haddad, Rafi Hazan, David Lenigas and Ferras Zalt. At the Meeting, shareholders adopted a special resolution approving a change in the name of the Corporation to “Elixxer Ltd.” or such other name as the Corporation’s directors may determine. The special resolution was supported by 98.94% of the votes cast at the Meeting. The Corporation intends to proceed with the name change as expeditiously as possible. Shareholders also adopted: a special

Merus Announces 2019 Annual General Meeting of Shareholders23.5.2019 14:00:00 CESTPressemelding

UTRECHT, The Netherlands, May 23, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the 2019 Annual General Meeting of Shareholders will be held on June 12, 2019 at 1:00 pm (CEST) at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clin